Mantle cell lymphoma (MCL) is a subtype of non-Hodgkin lymphoma characterized by the proliferation of B-cells in the mantle zone of lymphoid follicles. Extranodal and solid organ involvement indicates that the disease has spread beyond lymph nodes, affecting organs such as the spleen, liver, or gastrointestinal tract. Accurate coding with ICD-10 Code C83.19 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively manage and treat this aggressive malignancy.
What is ICD-10 Code C83.19 for Mantle cell lymphoma, extranodal and solid organ sites?
ICD-10 Code C83.19 specifically denotes mantle cell lymphoma with extranodal and solid organ involvement. This code is utilized when the lymphoma manifests outside of lymph nodes, indicating a more advanced stage of the disease. It is crucial for clinical documentation and billing to accurately reflect the extent of the disease, ensuring appropriate treatment plans and resource allocation.
ICD-10 Code C83.19 – Clinical Definition and Explanation of Mantle cell lymphoma, extranodal and solid organ sites
Mantle cell lymphoma, extranodal and solid organ sites, is a hematological malignancy that arises from B-lymphocytes. It is often associated with aggressive clinical behavior and requires prompt medical intervention. The disease can progress rapidly, leading to significant morbidity and mortality if not treated effectively.
Key Clinical Features:
- Commonly presents with lymphadenopathy, splenomegaly, and hepatomegaly.
- May involve gastrointestinal tract, bone marrow, and other solid organs.
- Associated with a poor prognosis and requires aggressive treatment strategies.
- Diagnosis often confirmed through biopsy and immunophenotyping.
ICD-10 Code C83.19 for Mantle cell lymphoma, extranodal and solid organ sites – SOAP Notes & Clinical Use
In clinical workflows, ICD-10 Code C83.19 is integral for documenting patient symptoms, assessments, and treatment plans. It aids in capturing the complexity of mantle cell lymphoma with extranodal involvement, ensuring comprehensive care in both acute and chronic settings.
What Does ICD-10 Code C83.19 for Mantle cell lymphoma, extranodal and solid organ sites Mean in SOAP Notes?
ICD-10 Code C83.19 connects subjective patient reports and objective clinical findings to a formal diagnosis of mantle cell lymphoma with extranodal involvement. This code is vital for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.
Treatment Options for ICD-10 Code C83.19 – Mantle cell lymphoma, extranodal and solid organ sites
Prompt treatment for mantle cell lymphoma with extranodal involvement is critical due to its aggressive nature. Management typically involves chemotherapy, targeted therapy, and possibly stem cell transplantation.
Antibiotic Therapy:
- Not applicable as mantle cell lymphoma is not an infectious disease.
Supportive Care:
- Management of symptoms such as pain and nausea.
- Nutritional support to maintain strength during treatment.
- Psychosocial support for patients and families.
Infection Control:
- Implement standard precautions to prevent infections.
- Monitor for signs of infection due to immunosuppression from treatment.
How to Document Symptoms of Mantle cell lymphoma, extranodal and solid organ sites (ICD-10 C83.19) in SOAP Notes
Subjective:
- Patient reports persistent fatigue and weight loss.
- Complaints of abdominal pain and early satiety.
- History of night sweats and fever.
- Notable increase in lymph node size over the past month.
Objective:
- Physical examination reveals splenomegaly and hepatomegaly.
- Lymph nodes are enlarged in cervical and axillary regions.
- Laboratory tests show elevated lactate dehydrogenase (LDH) levels.
- Imaging studies indicate involvement of the gastrointestinal tract.
Secure, compliant, and built for trust
HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn more
SOAP Note Guidelines for Diagnosing Mantle cell lymphoma, extranodal and solid organ sites (ICD-10 Code C83.19)
Assessment:
- Diagnosis: Mantle cell lymphoma, extranodal and solid organ sites, aggressive.
- ICD-10 Code: C83.19.
- Contributing factors: Advanced stage with systemic symptoms.
Plan:
- Initiate chemotherapy regimen (e.g., R-CHOP or similar).
- Consider referral for hematology/oncology consultation.
- Educate patient on treatment side effects and management.
- Schedule follow-up appointments for monitoring response to therapy.
Treatment & Plan Section for ICD-10 Code C83.19 – Mantle cell lymphoma, extranodal and solid organ sites
- First-line treatment typically includes combination chemotherapy.
- Consider targeted therapies such as ibrutinib for specific cases.
- Regular monitoring of blood counts and disease markers.
- Patient education on recognizing symptoms of complications.
Using ICD-10 Code C83.19 for Mantle cell lymphoma, extranodal and solid organ sites in Billing & SOAP Note Compliance
- Ensure accurate documentation of symptoms and clinical findings.
- Use C83.19 in settings where extranodal involvement is confirmed.
- Align treatment plans with clinical guidelines to support billing.
- Include relevant CPT codes that correspond to the services provided.
Related ICD-10 Codes Often Used with Mantle cell lymphoma, extranodal and solid organ sites
- C83.10 – Mantle cell lymphoma, unspecified site
- C83.11 – Mantle cell lymphoma, lymph nodes of head, face, and neck
- C83.12 – Mantle cell lymphoma, lymph nodes of axilla and upper limb
- C83.13 – Mantle cell lymphoma, lymph nodes of mediastinum
- C83.14 – Mantle cell lymphoma, lymph nodes of abdomen
ICD-10 Code C83.19 in Medical Billing and Insurance for Mantle cell lymphoma, extranodal and solid organ sites
ICD-10 Code C83.19 is essential for accurate billing in hospital, ER, or infectious disease care settings, reflecting the complexity of the patient's condition.
Billing Notes:
- Document all relevant clinical findings to support the diagnosis.
- Use C83.19 in conjunction with detailed treatment plans.
- Ensure compliance with payer requirements for documentation.
- Review coding guidelines regularly to maintain accuracy.
Common CPT Pairings:
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, intravenous, push, single or initial substance. |
| 96415 | Chemotherapy administration, intravenous, each additional substance. |
| 99223 | Initial hospital care, typically 70 minutes or more. |
| 85025 | Complete blood count with automated differential white blood cell count. |
Frequently Asked Questions
Common Questions About Using ICD-10 Code C83.19 for Mantle cell lymphoma, extranodal and solid organ sites
What are the common symptoms of mantle cell lymphoma?
Common symptoms include swollen lymph nodes, fatigue, weight loss, fever, and night sweats. Patients may also experience abdominal pain if the gastrointestinal tract is involved.
How is mantle cell lymphoma diagnosed?
Diagnosis typically involves a combination of physical examination, imaging studies, and biopsy of affected lymph nodes or tissues to confirm the presence of malignant B-cells.
What treatment options are available for mantle cell lymphoma?
Treatment often includes chemotherapy, targeted therapies, and possibly stem cell transplantation, depending on the stage and individual patient factors.
Is mantle cell lymphoma curable?
While mantle cell lymphoma is considered aggressive and challenging to treat, some patients may achieve remission with appropriate therapy. Long-term management is often necessary.
